Clinical trials: Venous Thromboembolic Event
Thromboembolic Events, Post-operative Bleeding
Frequency of Vascular Events With Short-term Thromboprophylaxis in Fast-track Hip and Knee-arthroplasty.
There are many different views regarding ideal duration and type of thromboprophylaxis after hip or knee surgery. An important factor in Fast-track surgery is early mobilization, which in itself is thought to prevent clotting.
- Trial name
- FETA (NCT01557725)
- Where
- 6 sites in Denmark
- Volunteers
- 4,924 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Venous Thromboembolism
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04735523
- Testing
- Dabigatran, Warfarin
- Where
- United States
- Volunteers
- 5,350 people
- Sponsor
- Brigham and Women's Hospital
Survey, Venous Thromboembolism
Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
In France, venous thromboembolic (VTE) disease is usually managed by vascular medicine physicians (VMP). The national OPTIMEV study, conducted more than 12 years ago among VMP practicing in hospital and in the community described…
- Conditions
- Survey, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- Observ-MTEV (NCT04272723)
- Where
- France
- Volunteers
- 383 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Burns
Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients
This study aims to assess the feasibility and safety of VTE prophylaxis for 3 modality regimens (Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours) in adult patients (≥18…
- Trial name
- NCT05237726
- Testing
- Enoxaparin 40 mg q24 hours, Enoxaparin 30 mg q12 hours, Unfractionated heparin 5000 U q8 hours
- Where
- Saudi Arabia
- Volunteers
- 20 people
- Sponsor
- King Abdullah International Medical Research Center
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery
The primary objective was to compare the efficacy of once daily [q.d] subcutaneous [s.c.] injections of Semuloparin sodium (AVE5026) with q.d. s.c.
- Trial name
- SAVE-HIP2 (NCT00721760)
- Testing
- Enoxaparin sodium, Semuloparin sodium
- Where
- 25 sites in United States, Argentina and 23 more
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Thromboembolism
Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism
[18F]GP1 targets platelet GPIIb/IIIa receptor in thrombus. [18F]GP1 PET/CT imaging will noninvasively assess thrombus in whole body with good sensitivity with information of thrombus.
- Trial name
- NCT02864810
- Testing
- [18F]GP1
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Asan Foundation
Venous Thromboembolism (VTE), Intensive Care Medicine
Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis
Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used.
- Conditions
- Venous Thromboembolism (VTE), Intensive Care Medicine, Venous Thromboembolism
- Trial name
- SOPHIE (NCT06958588)
- Testing
- Experimental: Hyperslim, Active Comparator #1
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Science Valley Research Institute
Cancer-associated Thrombosis, Genetic Predisposition
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy.
- Trial name
- ONCOTHROMB (NCT03114618)
- Where
- 9 sites in Spain
- Volunteers
- 416 people
- Sponsor
- Andres muñoz
Cancer, Venous Thromboembolism
Allo - Cancer - Thrombosis
Management of venous thromboembolism (VTE) in patients with cancer is complex and require the intervention of many specialized health professionals, in hospital but also at home and during follow-up.
- Trial name
- AlloTC (NCT03563924)
- Testing
- Setting up a specific care path "AlloTC" for management of TVE in patients with cancer
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Embolism, Deep Vein Thrombosis
Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism
The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central line catheter. The device is designed to be placed in the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01403090
- Testing
- Angel Catheter
- Where
- 2 sites in Colombia
- Volunteers
- 8 people
- Sponsor
- BiO2 Medical
Sickle Cell Disease, Venous Thromboembolism
Comparison of Thrombin Generation, Platelet Activation and Aggregation Profiles in Patients With Sickle Cell Disease Depending on Their SS or SC Genotype (DrepAgreg)
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crises called vaso-occlusive crises (VOC) and chronic inflammation.
- Trial name
- DrepAgreg (NCT07852442)
- Where
- 2 sites in France, Guadeloupe
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Venous Thromboembolism, Cancer
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer
In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.
- Trial name
- NCT00981903
- Testing
- Tinzaparin sodium
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- University of Southern California
Venous Thromboembolism
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
This study is a multicenter, double-blind, randomized, prospective phase 2 dose ranging study to evaluate the safety and efficacy of Dimolegin - DD217 in prevention of venous thromboembolic complications in patients underwent…
- Trial name
- NCT05189002
- Testing
- Dimolegin 40 mg, Dimolegin 60 mg, Fragmin
- Where
- 15 sites in Russia
- Volunteers
- 240 people
- Sponsor
- PharmaDiall Ltd.
Venous Thromboembolism, Pulmonary Embolism
Epidemiology of Venous Thromboembolism
More than 5 years ago the DVT FREE Registry was conceived. Its database consists of 5,451 ultrasound-confirmed DVT patients from 183 institutions.
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Cancer, Deep Vein Thrombosis
- Trial name
- NCT00456196
- Where
- United States
- Volunteers
- 5,451 people
- Sponsor
- Brigham and Women's Hospital
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital
Lung Neoplasms, Esophageal Neoplasms
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery
The purpose of this study is to determine whether the use of different dose of LMWH compared with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.
- Conditions
- Lung Neoplasms, Esophageal Neoplasms, Venous Thromboembolism
- Trial name
- NCT01267305
- Testing
- Fondaparinux, Nadroparin Calcium
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Shanghai Zhongshan Hospital
Lower Extremity Injuries, Venous Thromboembolism (VTE)
TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower Limb Trauma Requiring Immobilization
This is a prospective, multicenter, observational cohort study designed to externally validate the Trauma-Related Immobilization-related Prophylaxis (TRiP(cast)) score in Tunisian adults with acute lower-limb trauma requiring…
- Conditions
- Lower Extremity Injuries, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- TRiP-VALID (NCT07863115)
- Testing
- Low-Molecular-Weight Heparin (LMWH), Direct Oral Anticoagulants (DOACs), No Thromboprophylaxis Cohort
- Where
- Tunisia
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
Venous Thromboembolism
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE.
- Trial name
- MATHVTE (NCT03404635)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 1,300 people
- Sponsor
- Indiana University